Researchers Use Affymetrix Technology to Discover Why Some Breast Cancer Patients Resist Tamoxifen

Affymetrix Inc., (Nasdaq:AFFX) announced today that scientists at Cancer Research UK have used Affymetrix technology to discover the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment. Their findings are published in Nature(1).
Tamoxifen is given to most women for five years after they are first diagnosed with breast cancer to help prevent the disease from coming back. Some women develop resistance to the treatment after time, meaning their cancer is more likely to return.

Source: Affymetrix